Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis.

Signaling pathways engaged by angiogenic factors bFGF and VEGF in tumor angiogenesis are not fully understood. The current study identifies cytoplasmic tyrosine kinase c-Abl as a key factor differentially mediating bFGF- and VEGF-induced angiogenesis in microvascular endothelial cells. STI571, a c-Abl kinase inhibitor, only inhibited bFGF- but not VEGF-induced angiogenesis. bFGF induced membrane receptor cooperation between integrin beta(3) and FGF receptor, and triggered a downstream cascade including FAK, c-Abl, and MAPK. This signaling pathway is different from one utilized by VEGF that includes integrin beta(5), VEGF receptor-2, Src, FAK, and MAPK. Ectopic expression of wild-type c-Abl sensitized angiogenic response to bFGF, but kinase dead mutant c-Abl abolished this activity. Furthermore, the wild-type c-Abl enhanced angiogenesis in both Matrigel implantation and tumor xenograft models. These data provide novel insights into c-Abl's differential functions in mediating bFGF- and VEGF-induced angiogenesis.

[1]  D. Stupack,et al.  Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli , 2003, Science.

[2]  R. Shao,et al.  Human microvascular endothelial cells immortalized with human telomerase catalytic protein: a model for the study of in vitro angiogenesis. , 2004, Biochemical and biophysical research communications.

[3]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[4]  R. Soldi,et al.  Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor‐2 , 1999, The EMBO journal.

[5]  B. Eliceiri.  This Review is part of a thematic series on Integrins, which includes the following articles: Integrins and the Myocardium Functional Consequences of Integrin Gene Mutations in Mice Integrins in Vascular Development Integrin and Growth Factor Receptor Crosstalk , 2001 .

[6]  Leif E. Peterson,et al.  Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. , 2003, Cancer research.

[7]  A. Galloway,et al.  VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosis , 2006, Proceedings of the National Academy of Sciences.

[8]  A. Pendergast,et al.  Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway , 2001, Current Biology.

[9]  M. Detmar,et al.  Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. , 1996, The American journal of pathology.

[10]  K. Kumamoto,et al.  Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats. , 2002, Cancer research.

[11]  D. Sheppard,et al.  Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling , 2002, The Journal of cell biology.

[12]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[13]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[14]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[15]  Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. , 2001 .

[16]  C. Eaves,et al.  Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. , 2007, Journal of the National Cancer Institute.

[17]  I. Zachary,et al.  Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinase , 1997, FEBS letters.

[18]  Ruud P. M. Dings,et al.  Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. , 2007, Cancer research.

[19]  J. Folkman.  Tumor angiogenesis and tissue factor , 1996, Nature Medicine.

[20]  C. Heldin,et al.  Characterization of an imatinib-sensitive subset of high-grade human glioma cultures , 2006, Oncogene.

[21]  A. Kazlauskas,et al.  c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. , 1999, Genes & development.

[22]  Qingbo Xu,et al.  HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells , 2006, The Journal of cell biology.

[23]  L. Hood,et al.  Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas , 2007, Proceedings of the National Academy of Sciences.

[24]  M. Baccarani,et al.  Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia , 2006, Clinical Cancer Research.

[25]  M. Deckert,et al.  Abl‐SH3 binding protein 2, 3BP2, interacts with CIN85 and HIP‐55 , 2007, FEBS letters.

[26]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  C. Damsky,et al.  FAK integrates growth-factor and integrin signals to promote cell migration , 2000, Nature Cell Biology.

[28]  E. Brown,et al.  Inducible Tyrosine Phosphorylation of the β3 Integrin Requires the αv Integrin Cytoplasmic Tail* , 1996, The Journal of Biological Chemistry.

[29]  A. Ullrich,et al.  Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. , 1996, Cancer research.

[30]  D. Coppola,et al.  Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors , 2004, Oncogene.

[31]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[32]  A. Mantovani,et al.  Molecular mechanisms of blood vessel formation. , 1997, Trends in biochemical sciences.

[33]  S. Rabbani,et al.  A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. , 2007, Cancer research.

[34]  J. Lindquist,et al.  Cooperation between VEGF and beta3 integrin during cardiac vascular development. , 2007, Blood.

[35]  P. Schwartzberg,et al.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.

[36]  D. Schlaepfer,et al.  The Focal Adhesion Kinase‐‐A Regulator of Cell Migration and Invasion , 2002, IUBMB life.

[37]  T. Byzova,et al.  A mechanism for modulation of cellular responses to VEGF: activation of the integrins. , 2000, Molecular cell.

[38]  I. Zachary,et al.  Vascular Endothelial Growth Factor Stimulates Tyrosine Phosphorylation and Recruitment to New Focal Adhesions of Focal Adhesion Kinase and Paxillin in Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[39]  B. Zetter,et al.  Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. , 1996, Growth factors.

[40]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[41]  P. Jones,et al.  Regulation of Tenascin-C, a Vascular Smooth Muscle Cell Survival Factor that Interacts with the αvβ3 Integrin to Promote Epidermal Growth Factor Receptor Phosphorylation and Growth , 1997, The Journal of cell biology.

[42]  F. Giles,et al.  Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2007, Clinical lymphoma & myeloma.

[43]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[44]  D. Donner,et al.  Vascular Endothelial Cell Growth Factor Promotes Tyrosine Phosphorylation of Mediators of Signal Transduction That Contain SH2 Domains , 1995, The Journal of Biological Chemistry.

[45]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[46]  T. Cotter,et al.  Abl expression in human fetal and adult tissues, tumours and tumour microvessels , 1997, The Journal of pathology.

[47]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[48]  Levon M Khachigian,et al.  Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth , 2003, Nature Medicine.

[49]  E. Ruoslahti,et al.  αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF , 1997 .